Roche secures EC approval for Rozlytrek to treat solid tumours and NSCLC
Swiss healthcare firm Roche has received the European Commission (EC) conditional marketing authorisation for Rozlytrek (entrectinib) to treat a type of solid tumours. The EC approved Rozlytrek to